Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Prothena Corporation PLC    PRTA   IE00B91XRN20

PROTHENA CORPORATION PLC (PRTA)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
13.21(c) 13.36(c) 13.62(c) 13.34(c) 14.25(c) Last
500 603 273 897 219 045 3 875 985 1 531 220 Volume
+4.02% +1.14% +1.95% -2.06% +6.82% Change
More quotes
Financials (USD)
Sales 2018 6,23 M
EBIT 2018 -180 M
Net income 2018 -179 M
Debt 2018 -
Yield 2018 -
Sales 2019 19,7 M
EBIT 2019 -99,4 M
Net income 2019 -101 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 91,1x
Capi. / Sales2019 28,9x
Capitalization 568 M
More Financials
Company
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories.Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease.The company... 
More about the company
Surperformance© ratings of Prothena Corporation PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTHENA CORPORATION PLC
09/13SEPTEMBER 17TH DEADLINE ALERT : Glancy Prongay & Murray LLP Reminds Investors of..
BU
09/02EQUITY NOTICE : Rosen Law Firm Announces Filing of Securities Class Action Lawsu..
BU
08/29PROTHENA : The Law Offices of Howard G. Smith Reminds Investors of Extended Lead..
BU
07/24INVESTOR ALERT : Kaplan Fox Announces Investigation Of Prothena Corporation plc
PR
07/21GLANCY PRONGAY & MURRAY LLP : Announces Extended Lead Plaintiff Deadline in Secu..
BU
07/20Free Technical Research on Riot Blockchain and Three More Biotech Equities
AC
07/18PROTHENA : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Inves..
PR
07/17ROBBINS ARROYO LLP : Prothena Corporation Public Limited Company (PRTA) Misled S..
BU
07/12PROTHENA CORPORATION PLC : Pomerantz Law Firm Reminds Shareholders with Losses o..
AC
07/11MONDAY DEADLINE ALERT : The Schall Law Firm Announces it is Investigating Claims..
BU
More news
Sector news : Bio Therapeutic Drugs
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
02:56aProthena $PRTA Trading 6.8% Higher  
09/24MOST ACTIVE ALERT: $PRTA PROTHENA CORP PLC ORDIN ? TradeIdeas via  
09/24SOCIAL ACTIVITY: $PRTA - PROTHENA CORP PLC ORDIN ? TradeIdeas via ?  
09/20$260,000.00 in Sales Expected for Prothena Co. PLC $PRTA This Quarter  
09/18Prothena $PRTA with 1,000 March $12 puts being sold to open for $1.15, popula..
2
More tweets
Qtime:26
News from SeekingAlpha
08/16The Battle For Best-In-Class In ATTR Has Begun 
08/07Prothena misses by $0.37, misses on revenue 
06/26Prothena announces appointment of Tran B. Nguyen as COO 
06/21YOUR DAILY PHARMA SCOOP : Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta S.. 
06/19Prothena up 1% after publishing positive Parkinson's treatment data 
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 14,3 $
Spread / Average Target 0,25%
EPS Revisions
Managers
NameTitle
Gene G. Kinney President, Chief Executive Officer & Director
Lars G. Ekman Chairman
Tran B. Nguyen Chief Operating & Financial Officer
Wagner Zago Chief Scientific Officer
Richard T. Collier Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTHENA CORPORATION PLC-61.99%568
GILEAD SCIENCES5.56%97 887
VERTEX PHARMACEUTICALS21.56%46 021
REGENERON PHARMACEUTICALS3.79%41 426
NEUROCRINE BIOSCIENCES, INC.56.01%10 822
GENMAB2.04%10 170